Cantabio Pharmaceuticals Liabilities 2024

Cantabio Pharmaceuticals Aktienanalyse

What does Cantabio Pharmaceuticals do?

Cantabio Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company was founded in 2009 by Professor Gou-Ping Chen, an expert in protein structures and functions. Cantabio Pharmaceuticals was established specifically to address neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, which are among the largest and most prevalent diseases in the aging population. The business model of Cantabio Pharmaceuticals is based on the development of products that have been developed based on new insights in molecular research and increased understanding of neurodegenerative diseases. By collaborating with universities, research laboratories, and other industry partners, the company employs an innovation strategy to present novel solutions to the public. For its research and products, the company focuses on three main areas: - Drug discovery - the company has a variety of products in the pipeline, from discovery to clinical phases, which are strictly regulated by the FDA. - Protein and antibody manufacturing - the company uses the latest technologies to manipulate proteins to maximize their beneficial effects and optimize their potential therapeutic efficacy. - Diagnostic tools - the company also develops diagnostic tests and analysis tools for the detection of biomarkers to enable faster and more accurate diagnosis. In basic research, the company has discovered a novel class of proteins called Alpha-Synuclein inhibitors. Alpha-Synuclein is a protein that is associated with Parkinson's disease due to its overproduction and accumulation. Through experiments, Cantabio scientists have discovered substances to inhibit or even reduce its production and accumulation. These discoveries have gained significant attention in the scientific community and could contribute to important advances in understanding and overcoming brain pathologies. Cantabio Pharmaceuticals' products include a range of treatments applicable to specific diseases. One of the company's most important products is the novel drug CB2813, which targets the treatment of Alzheimer's and other neurodegenerative diseases. CB2813 represents an innovation in the treatment of Alzheimer's by combating the progression of the disease at the molecular level and strengthening the brain's biochemical protection. Another product of Cantabio Pharmaceuticals is the Alpha-Synuclein inhibitor CNS5874, which is used in Parkinson's disease. Parkinson's disease is characterized by the loss of dopamine receptors and the accumulation of Alpha-Synuclein protein. Administration of CNS5874 can reduce the accumulated Alpha-Synuclein protein in the brain regions significantly affected by the disease and promote improvement in patient behavior. Overall, Cantabio Pharmaceuticals is a leading company in the field of neurodegenerative diseases, focusing on the development of innovative treatment methods. In order to expand its pipeline and improve the available treatment options for patients, the company is constantly developing new products, some of which are already in research and clinical development. Cantabio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Cantabio Pharmaceuticals's Liabilities

Cantabio Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cantabio Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cantabio Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cantabio Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cantabio Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cantabio Pharmaceuticals stock

What is the level of liabilities of Cantabio Pharmaceuticals this year?

Cantabio Pharmaceuticals has a debt balance of 0 USD this year.

What were the liabilities of Cantabio Pharmaceuticals compared to the previous year?

The liabilities of Cantabio Pharmaceuticals have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Cantabio Pharmaceuticals?

High liabilities can pose a risk for investors of Cantabio Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Cantabio Pharmaceuticals?

Low liabilities mean that Cantabio Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Cantabio Pharmaceuticals affect the company?

An increase in liabilities of Cantabio Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Cantabio Pharmaceuticals affect the company?

A decrease in the liabilities of Cantabio Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Cantabio Pharmaceuticals?

Some factors that can influence the liabilities of Cantabio Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Cantabio Pharmaceuticals so important for investors?

The liabilities of Cantabio Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Cantabio Pharmaceuticals take to modify the liabilities?

To change its liabilities, Cantabio Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Cantabio Pharmaceuticals pay?

Over the past 12 months, Cantabio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cantabio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cantabio Pharmaceuticals?

The current dividend yield of Cantabio Pharmaceuticals is .

When does Cantabio Pharmaceuticals pay dividends?

Cantabio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cantabio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cantabio Pharmaceuticals located?

Cantabio Pharmaceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Cantabio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cantabio Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Cantabio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Cantabio Pharmaceuticals in the year 2023?

In the year 2023, Cantabio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cantabio Pharmaceuticals pay out the dividend?

The dividends of Cantabio Pharmaceuticals are distributed in USD.